Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Nutex Health (NUTX) over the last 16 years, with FY2024 value amounting to $40.6 million.

  • Nutex Health's Cash & Equivalents rose 25397.69% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.0 million, marking a year-over-year increase of 25397.69%. This contributed to the annual value of $40.6 million for FY2024, which is 8471.0% up from last year.
  • Per Nutex Health's latest filing, its Cash & Equivalents stood at $40.6 million for FY2024, which was up 8471.0% from $22.0 million recorded in FY2023.
  • In the past 5 years, Nutex Health's Cash & Equivalents ranged from a high of $40.6 million in FY2024 and a low of $26931.0 during FY2020
  • In the last 5 years, Nutex Health's Cash & Equivalents had a median value of $34.3 million in 2022 and averaged $26.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 9747.23% in 2020, then surged by 13401415.84% in 2021.
  • Nutex Health's Cash & Equivalents (Annual) stood at $26931.0 in 2020, then soared by 134014.16% to $36.1 million in 2021, then fell by 5.16% to $34.3 million in 2022, then plummeted by 35.77% to $22.0 million in 2023, then surged by 84.71% to $40.6 million in 2024.
  • Its Cash & Equivalents stands at $40.6 million for FY2024, versus $22.0 million for FY2023 and $34.3 million for FY2022.